Treatment Options

The treatment landscape for MCL has evolved significantly. Here's an overview of current approaches.

Treatment Options

The treatment landscape for mantle cell lymphoma (MCL) continues to change, with more options now available than even a few years ago.

Treatment depends on the subtype and stage of disease, your age and overall health, any prior therapies you have received, and your personal goals and preferences. Your care team will help tailor a plan that is right for you. haematologica+2

Chemotherapy and Immunotherapy

Traditional chemotherapy combined with an immune‑based drug called rituximab (an antibody that targets CD20 on lymphoma cells) is still used, especially for people who are newly diagnosed. Common chemo‑immunotherapy combinations include: canadianhematologytoday+1

  • R‑CHOP: rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone.[canadianhematologytoday]
  • Cytarabine‑containing regimens such as R‑DHAP or other high‑dose cytarabine‑based treatments, which are more intensive and often used in younger, fitter patients.haematologica+1
  • Bendamustine plus rituximab (BR), a commonly used and relatively well‑tolerated option, especially in older adults.haematologica+1
  • R‑Hyper‑CVAD, an intensive alternating regimen used in selected fit patients at experienced centers.[pmc.ncbi.nlm.nih]

These regimens can be used alone, followed by a stem cell transplant in some patients, or combined with newer targeted drugs in clinical trials.pubmed.ncbi.nlm.nih+1

More information:

Targeted Therapies

Targeted therapies are pills or infusions that block specific signals cancer cells use to grow and survive. For MCL, key targeted options include: pubmed.ncbi.nlm.nih+1

  • BTK inhibitors (BTKi): Drugs such as ibrutinib, acalabrutinib, and zanubrutinib block an enzyme called Bruton’s tyrosine kinase (BTK) that MCL cells rely on. These medicines are now a mainstay for relapsed disease and are being studied as part of initial treatment for some patients. New “non‑covalent” BTK inhibitors (for example, pirtobrutinib) are being developed for patients whose lymphoma no longer responds to standard BTKi. pubmed.ncbi.nlm.nih+3
  • BCL‑2 inhibitor: Venetoclax targets a protein that helps lymphoma cells avoid cell death and is often used in combination with BTK inhibitors or antibodies in relapsed disease and in clinical trials. pubmed.ncbi.nlm.nih+1
  • Proteasome inhibitor: Bortezomib interferes with the cell’sprotein‑disposal system and can be part of combination regimens for some patients.haematologica+1
  • mTOR inhibitor: Temsirolimus targets a cell‑growth pathway and may be considered in selected relapsed cases when other options are not suitable.[haematologica]

In many centers, BTK inhibitors are preferred at first relapse, and treatment decisions after a BTKi depend on how well and how long the BTKi worked. pubmed.ncbi.nlm.nih+1

More information:

General strategies and novel drugs:

Relapsed/refractory overview (including BTKi and venetoclax):

Stem Cell Transplantation

For some younger or medically fit patients who respond well to initial treatment, an autologous stem cell transplant (using the patient’s own blood‑forming stem cells) may be used to deepen the response and help the remission last longer. With the growth of BTK inhibitors and cellular therapies, the role of transplant is being individualized based on risk factors (such as very aggressive disease or certain genetic changes) and patient preferences. Allogeneic (donor) stem cell transplant is generally reserved for selected patients with high‑risk or repeatedly relapsing disease when other options, including CAR‑T, are not appropriate or available. pmc.ncbi.nlm.nih+3

More information:

CAR‑T Cell Therapy and Other T‑Cell–Redirecting Therapies

CAR‑T cell therapy is an advanced form of immunotherapy in which a patient’s own T cells are engineered in a lab to recognize and attack lymphoma cells. Brexucabtagene autoleucel (Tecartus) is an approved CAR‑T cell therapy for adults with relapsed or refractory MCL after at least one prior treatment; many patients in studies had already received a BTK inhibitor and several other treatments. In these patients, CAR‑T therapy produced high response rates, including deep and sometimes long‑lasting remissions, but it can have serious side effects and is given only at specialized centers.pmc.ncbi.nlm.nih+3

Newer treatments can redirect T cells without removing them from the body, using “bispecific antibodies” that link T cells (immune cells) directly to lymphoma cells. Glofitamab, a CD20×CD3 bispecific antibody, has shown high complete response rates and durable remissions in heavily pretreated patients with relapsed or refractory MCL, including those with high‑risk features, in phase I/II trials. Other bispecific antibodies and antibody‑drug conjugates are being studied and may expand options after BTK inhibitors in the near future. These T‑cell–redirecting therapies are particularly important for patients whose disease has come back after, or not responded to, BTK inhibitors. pmc.ncbi.nlm.nih+6

More information:

Brexucabtagene autoleucel (Tecartus) data:

T‑cell–redirecting approaches and bispecific antibodies:

Watch and Wait (Active Surveillance)

Some people have a slower‑growing form of MCL, often called indolent or leukemic non‑nodal MCL. In these cases, immediate treatment is not always necessary, and a “watch and wait” or active surveillance approach—with regular checkups, blood tests, and scans—can be safe. Treatment is started if there are signs that the lymphoma is growing, blood counts are changing, or symptoms are developing. canadianhematologytoday+1

More information:

Clinical Trials

Clinical trials are a key part of MCL care and offer access to promising new drugs and combinations that are not yet widely available. Current trials include studies of: pubmed.ncbi.nlm.nih+1

  • New BTK inhibitors and combinations with venetoclax, antibodies, or chemotherapy. pubmed.ncbi.nlm.nih+1
  • Different ways to use CAR‑T cell therapy, including earlier in the disease course or together with BTK inhibitors. pmc.ncbi.nlm.nih+1
  • Bispecific antibodies and other immune‑based treatments, alone or in combination with antibody‑drug conjugates. pubmed.ncbi.nlm.nih+2

Because the field is moving quickly, asking about clinical trial options at diagnosis and at each relapse can help ensure you are aware of all available choices.haematologica+1

More information and scientific updates:

Review of strategies after BTK inhibitors and emerging agents:

Broader review of relapsed/refractory MCL options:

Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.